

12th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

BARCELONA, 07-09 NOVEMBER, 2012



www.ifmad.org

CHAIRMAN: Siegfried KASPER (Austria)

CO-CHAIRMAN: Stuart A. MONTGOMERY (United Kingdom)



Final Programme



SCIENTIFIC COMMITTEE

Chairman

Siegfried Kasper (Austria)

Co-Chairman

Stuart A. Montgomery (UK)

Scientific Advisers

C. Allgulander (Sweden), **C.A. Altamura** (Italy),
C. Arango (Spain), **D. Baldwin** (UK), **B. Bandelow** (Germany),
M. Bauer (Germany), **P. Blier** (Canada),
G. Burrows (Australia), **G.B. Cassano** (Italy), **K. Demyttenaere** (Belgium),
J. Den Boer (The Netherlands), **T. Dinan** (Ireland), **E. Eriksson** (Sweden),
N. Fineberg (UK), **S.H. Kennedy** (Canada),
D. Lecic Tosevski (Serbia), **M. Maj** (Italy), **A.A. Mathé** (Sweden),
J. Mendlewicz (Belgium), **H.J. Möller** (Germany), **S. Pallanti** (Italy),
G. Papadimitriou (Greece), **G. Papakostas** (USA), **Z. Rihmer** (Hungary),
T. Roth (USA), **A.F. Schatzberg** (USA), **A. Serretti** (Italy),
D.J. Stein (South Africa), **E. Vieta** (Spain), **L. Von Knorring** (Sweden),
D. Winkler (Austria), **S. Yamawaki** (Japan), **A. Young** (UK),
J. Zohar (Israel)

IMPORTANT ADDRESSES

Organizing Secretariat



Publi Créations

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: ifmad@publiccreations.com - Website: www.ifmad.org



Congress Venue

Hotel Rey Juan Carlos I

Avenida Diagonal, 661-671
08028 Barcelona
Spain



Scientific Committee / Important addresses **2**

Welcome Letter / Acknowledgement **4**

Programme Overview **5**

Final Programme **6**

Scientific Information **11**

Congress venue / General Information **13**

www.ifmad.org





WELCOME LETTER

To all prospective delegates,

It is our pleasure to welcome you in Barcelona to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).

The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegiate atmosphere, and digested over dinner.

The meetings are always enjoyable and informative and along with the usual updates on new treatments in other areas this year's IFMAD will be an efficient way of catching up with the latest developments.

This year topics that will be addressed include educational strategies to prevent suicide, the place of antidepressants in bipolar depression, new approaches in treating alcohol abuse, improving placebo control groups and a core focus will be on the new antidepressants on the horizon.

We are pleased to welcome you in Barcelona and have you with us again this year.

Siegfried Kasper,
Chairman

Stuart A. Montgomery,
Co-Chairman

ACKNOWLEDGEMENT

*The Organizing Committee expresses their gratitude
for their contribution of unrestricted educational grants*

Lundbeck A/S 

for their contribution as Sponsor of Symposia

Pierre Fabre Medicament 

for their contribution as sponsor of the speaker's dinner

Wisepress LTD

for their participation in the exhibition

PROGRAMME OVERVIEW



Wednesday, November 07	Thursday, November 08	Friday, November 09
	09.00/10.30 SO 03 Broad-spectrum symptom control in bipolar disorder - what are the challenges?	09.00/10.30 SO 08 Cognitive dysfunction of depression – a symptom that we fail to treat?
	10.30/11.00 <i>Coffee break</i>	10.30/11.00 <i>Coffee break</i>
	11.00/12.30 SO 04 Hot topics in Mood disorders	11.00/12.30 SO 09 Developments in the treatment of Anxiety Disorders
	12.30/13.30 <i>Lunch</i>	12.30/13.30 <i>Lunch</i>
	13.30/15.00 SO 05 Optimizing treatment outcomes in depression and anxiety disorders	13.30/15.30 SO 10 New targets for depression
14.30/16.30 SO 01 Progress in Bipolar Disorder	15.00/16.00 Debate: SO 06 Antidepressant response is clearcut	
16.30/16.45 <i>Coffee break</i>	16.00/16.30 <i>Coffee break</i>	
16.45/18.15 SO 02 Advances in treatment of resistant depression	16.30/18.00 SO 07 Negative, cognitive and depressive symptoms in schizophrenia	
18.15/19.15 <i>Opening Ceremony</i>		



FINAL PROGRAMME

WEDNESDAY, 07 November 2012

14.30-16.30 SO 01 PROGRESS IN BIPOLAR DISORDER

Chair: **Siegfried KASPER (Austria)**
Allan YOUNG (United Kingdom)

14.30-15.00 SO 0101 Treatment of mixed states
Eduard VIETA (Spain)

15.00-15.30 SO 0102 Strategies towards optimising treatment
response in bipolar disorder
Isaac SCHWEITZER (Australia)

15.30-16.00 SO 0103 Treatment of bipolar depression
Allan YOUNG (UK)

16.00-16.30 SO 0104 Observational vs randomised controlled studies
Rico NIL (Switzerland)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

16.30-16.45 Coffee break

16.45-18.15 SO 02 ADVANCES IN TREATMENT OF RESISTANT DEPRESSION

Chair: **Alessandro SERRETTI (Italy)**
Eduard VIETA (Spain)

16.45-17.15 SO 0201 Should we stop raising the dose
in non-responders
Rasmus LICHT (Denmark)

17.15-17.45 SO 0202 Are two antidepressants better than one?
Michael BAUER (Germany)

17.45-18.15 SO 0203 Pharmacogenetics in clinical practice:
are we close?
Alessandro SERRETTI (Italy)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

18.15-19.15 Opening Ceremony



THURSDAY, 08 November 2012

09.00-10.30 SO 03 BROAD-SPECTRUM SYMPTOM CONTROL IN BIPOLAR DISORDER - WHAT ARE THE CHALLENGES?

09.00-09.10 Chairman's introduction: **Heinz GRUNZE (Germany)**

09.10-09.30 **SO 0301** Asenapine: the first tetracyclic antipsychotic
Pierre BLIER (Canada)

09.30-09.55 **SO 0302** Bipolar disorder: a multidimensional disorder
Andrea FAGIOLINI (Italy)

09.55-10.15 **SO 0303** Improving patient outcome with asenapine
Heinz GRUNZE (UK)

10.15-10.30 Panel discussion

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

10.30-11.00 **Coffee break**

11.00-12.30 SO 04 HOT TOPICS IN MOOD DISORDERS

Chair: **Borwin BANDELOW (Germany)**
Elias ERIKSSON (Sweden)

11.00-11.30 **SO 0401** Making sense in making guidelines
Lucas REMS (Germany)

11.30-12.00 **SO 0402** Educational strategies for preventing suicide: review of studies in Slovenia, Gotland and Germany
Saska ROSKAR (Slovenia)

12.00-12.30 **SO 0403** Why do celebrities die young?
Borwin BANDELOW (Germany)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

12.30-13.30 **Lunch**



FINAL PROGRAMME

13.30-15.00 SO 05 OPTIMIZING TREATMENT OUTCOMES IN DEPRESSION AND ANXIETY DISORDERS

Chair: **Alan WADE (UK)**

13.30-14.30 SO 0501 Combining antidepressants from the get-go - the state of the evidence for (and against) antidepressant combinations as first-line treatment in Major Depressive Disorder

Daniel MERON (UK)

14.00-14.30 SO 0502 What can prescription databases or real-life usage teach us about reaching optimal treatment outcomes

Yoram BARAK (Israel)

14.30-15.00 SO 0503 Escitalopram MELTZ – what do patients say about their experience?

Alan WADE (UK)

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

➤ *Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.*

15.00-16.00 SO 06 DEBATE: ANTIDEPRESSANT EFFICACY IS CLEARCUT

Chair: **Siegfried KASPER (Austria)**

Pro: **Elias ERIKSSON (Sweden)**

Contra: **Corrado BARBUI (Italy)**



16.00-16.30

Coffee break

16.30-18.00

SO 07 NEGATIVE, COGNITIVE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIA

Chair: ***Hans-Juergen MÖLLER (Germany)***

Stefan LEUCHT (Germany)

16.30-17.00

SO 0701 Depressive and negative symptoms - are they really separate?

Hans-Juergen MÖLLER (Germany)

17.00-17.30

SO 0702 New treatments for cognitive symptoms in schizophrenia

Raimund BULLER (France)

17.30-18.00

SO 0703 Treatment of affective or negative symptoms of schizophrenia

Stefan LEUCHT (Germany)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.



FRIDAY, 09 November 2012

09.00-10.30 SO 08 COGNITIVE DYSFUNCTION OF DEPRESSION - A SYMPTOM THAT WE FAIL TO TREAT?

Chair: **Stuart A. MONTGOMERY (UK)**

09.00-09.30 SO 0801 Current antidepressant treatments: what do we have and what do we need?

Philip COWEN (UK)

09.30-10.00 SO 0802 Assessing cognitive dysfunction in the depressed patient

Barbara SAHAKIAN (UK)

10.00-10.30 SO 0803 Review of current evidence for treatment of cognitive dysfunction of depression

Siegfried KASPER (Austria)

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

10.30-11.00 Coffee break

11.00-12.30 SO 09 DEVELOPMENTS IN THE TREATMENT OF ANXIETY DISORDERS

Chair: **Torgny SVENSSON (Sweden)**

Stefano PALLANTI (Italy)

11.00-11.30 SO 0901 Sexual Disorders and OCD

Jose MENCHON (Spain)

11.30-12.00 SO 0902 Is hoarding a separate disorder?

Stefano PALLANTI (Italy)

12.00-12.30 SO 0903 Long term treatment of anxiety disorders and OCD

David BALDWIN (UK)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

12.30-13.30 Lunch



FINAL PROGRAMME

13.30-15.30 SO 10 NEW TARGETS FOR DEPRESSION

Chair: **David BALDWIN (UK)**

Siegfried KASPER (Austria)

13.30-14.00 SO 1001 New Leads for Improved Treatment of Depression

Torgny SVENSSON (Sweden)

14.00-14.30 SO 1002 The role of neuroinflammation in major depression

Johan den BOER (The Netherlands)

14.30-15.00 SO 1003 Cardiovascular outcome in MDD

Timothy DINAN (Ireland)

15.00-15.30 SO 1004 Poetry and the Measurement of Depression - a personal journey

Siegfried KASPER (Austria)

Stuart MONTGOMERY (UK)

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation





P 1. Obsessive-compulsive symptoms in schizophrenia

Azizeh Afkhami

Tehran University of Medical Sciences (TUMS), Iran

P 02. A population pharmacokinetic meta-analysis of vortioxetine (Lu AA21004) in healthy subjects

Johan Areberg¹, Grace Chen², Himanshu Naik², Kamilla B. Pedersen¹, Mayid Vakilynejad²¹

H. Lundbeck A/S, Valby, Denmark; ²Takeda Global Research & Development Center Inc, Deerfield, USA

P 03. Intervention for a sleep health program on the basis of cognitive behavioral therapy through e-mail newsletters for Japanese students

Kenichi Asano¹, Ikuko Ishimura²

¹Research Center for Child Mental Development, Graduate School of Medicine, Chiba University, Chiba, Japan; ²Tokyo Seitoku University, Chiba, Japan

P 04. The effects of antidepressant monotherapy versus adjunctive therapy with an atypical antipsychotic in new-onset major depressive disorder

Daeup Baek

Dongnae Bongseng Hospital, Busan, South Korea

P 05. Prefrontal cordance in the outcome prediction of 1-Hz, right-sided, prefrontal rTMS in patients with depression.

Martin Bares, Tomas Novak

Third Faculty of Medicine, Charles University, Prague, Czech Republic

P 06. Anxiety of first cadaver demonstration in medical, dentistry and pharmacy faculty students

Ayşe Hilal Bati¹, Figen Govsa², Mehmet Asim Ozer², Yelda Pinar²

¹Ege University, Faculty of Medicine, Department of Medical Education, Izmir, Turkey,

²Ege University, Faculty of Medicine, Department of Anatomy, Izmir, Turkey

P 07. Newly-Graduated Physicians' Perceived Stress Before Specialization Exam

Ayşe Hilal Bati¹, Nazan Karaoglu²

¹Assistant Professor, Ege University, Faculty of Medicine, Department of Medical Education, Bornova-Izmir, Turkey; ²Associate Professor, Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Education and Informatics, Konya, Turkey



P 08. Attitudes of general practitioners towards training in mental health

Maite Bel, Raquel Borrego Leal, Carlos Conesa, Antonio Corominas, Ana Falces, Isabel Frigola, Teresa Sarmiento

Department of Mental Health, Fundació Privada Hospital de Mollet, Barcelona, Spain

P 09. Low Adiponectin and High Resistin Levels in Panic Disorder

Yasin Bez¹, Mahmut Bulut¹, Yuksel Kivrak², Kaya Mehmet Cemal¹, Yunce Muharrem⁴, Arı Mustafa⁵, Öztürk Oktay Hasan³

¹Dicle University; Department of Psychiatry, Diyarbakir, Turkey; ²Kafkas University; Department of Psychiatry, Kars, Turkey; ³Mustafa Kemal University; Department of Biochemistry, Hatay, Turkey; ⁴Dicle University; Department of Biochemistry, Diyarbakir, Turkey; ⁵Mustafa Kemal University; Department of Psychiatry, Hatay, Turkey

P 10. Partial Inactivation of Pon1 Activity and Increased Lipid Hydroperoxide Levels that point out Oxidative Stress in Generalized Anxiety Disorder

Emhan Ali³, Sir Aytelin¹, Mahmut Bulut¹, Karabab a Ibrahim F.³, Gunes Mehmet¹, Kaya Mehmet Cemal¹, Aksoy Nurten⁴, Selek Salih², Bez Yasin¹

¹Dicle University; Department of Psychiatry, Diyarbakir, Turkey; ²Istanbul Medeniyet University, Department of Psychiatry, Istanbul, Turkey; ³Harran University, Department of Psychiatry, Sanliurfa, Turkey; ⁴Harran University, Department of Biochemistry, Sanliurfa, Turkey

P 11. Affective Manifestations of Stiff-Person Syndrome: A Case Report with Clinical Considerations

Rebecca Burson^{1,2,3}

¹United States Air Force, San Antonio, USA; ²University of Texas Health Science Center San Antonio, San Antonio, USA; ³Psychiatry RESIDENT, PGY-IV, San Antonio, USA

P 12. The role of gender in the relationship of personality and parenting styles with mood and anxiety symptoms

Laura Camacho Guerrero¹, María Sígri Gallego Moya¹, Manuel Ignacio Ibáñez Ribes¹, Laura Mezquita Guillamón¹, Jorge Moya Higuera², Generós Ortet Fabregat¹, Helena Villa Martín¹, Ana María Viruela Royo¹

¹Universitat Jaume I, Castellon, Spain; ²universitat De Lleida, Lleida, Spain



P 13. Relating individual differences in trait-anxiety to children's memory for emotional information: An investigation using illustrated emotional stories

Lavinia Cheie, Laura Visu-Petra

Developmental Psychology Lab, Department of Psychology, Babeş-Bolyai University, Cluj-Napoca, Romania

P 14. The Cardiovascular Safety of Escitalopram at High Dosage

Gordon Crawford¹, Alan Wade¹, David Young²

¹CPS Research, Glasgow, United Kingdom; ²Strathclyde University, Glasgow, United Kingdom

P 15. Comorbid Panic Disorder and Suicide Attempts in Major Depressive Disorder

Kim Chan-Hyung¹, Roh Daeyoung^{1,2}, Nam Yoon-Young³

¹Department of Psychiatry, Yonsei University College of Medicine, Seoul ; ²Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul ; ³Division of Planning and Public Relations, Seoul National Hospital, Seoul, South Korea

P 16. A retrospective case series of bipolar patients during pregnancy: lithium prophylaxis, risk of recurrences and maternal/neonatal complications

Raffaella Ardu², Alberto Bocchetta¹, Paolo Carta², Caterina Chillotti², Valeria Deiana¹, Maria Del Zompo^{1,2}, Mirko Manchia¹

¹Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy; ²Unit of Clinical Pharmacology, University-Hospital of Cagliari, Cagliari, Italy

P 17. Perception of partner relationship and anxiety symptoms

Katarzyna Cyranka¹, Edyta Dembińska¹, Katarzyna Klasa², Łukasz Müldner-Nieckowski¹, Krzysztof Rutkowski¹, Jerzy A. Sobański¹

¹Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland; ²Department of Psychotherapy, University Hospital, Kraków, Poland

P 18. Personality traits changing with improvement of various anxiety symptoms

Katarzyna Cyranka¹, Edyta Dembińska¹, Katarzyna Klasa², Łukasz Müldner-Nieckowski¹, Krzysztof Rutkowski¹, Jerzy A. Sobański¹

¹Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland; ²Department of Psychotherapy, University Hospital, Kraków, Poland



P 19. Changes in the profile of diagnoses of patients treated with psychotherapy in a day hospital over the past 25 years. Increase in the anxiety disorders' rate?

Katarzyna Cyranka¹, Edyta Dembińska¹, Katarzyna Klasa², Łukasz Müldner-Nieckowski¹, Krzysztof Rutkowski¹, Jerzy A. Sobański¹

¹Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland;

²Department of Psychotherapy, University Hospital, Kraków, Poland

P 20. Error monitoring in major depressive disorder with psychomotor retardation: an fMRI study

Bernard Sabbe¹, Ellen R.A De Bruijn², Marianne Destoop¹

¹Collaborative Antwerp Psychiatric Research Institute, Antwerp, Belgium; ²Leiden Institute for Brain and Cognition, Leiden, Netherlands

P 21. Duplication of GTF2I results in separation anxiety in mice and humans

Joana Dida^{1,2}, Carolyn B. Mervis³, Emily Lam², Nicole A. Crawford-Zelli³, Edwin J. Young², Danielle R. Henderson³, Tuncer Onay⁴, Colleen A. Morris⁵, Janet Woodruff-Borden³, John Yeomans¹, Lucy R. Osborne^{2,6,7}

¹Department of Psychology, Centre for Biological Timing and Cognition, University of Toronto, ON Canada; ²Institute for Medical Science, University of Toronto, ON, Canada;

³Department of Psychological and Brain Sciences, University of Louisville, Louisville, KY; ⁴Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada;

⁵Department of Pediatrics, University of Nevada School of Medicine, Las Vegas, NV;

⁶Department of Medicine, University of Toronto, ON, Canada; ⁷Department of Molecular Genetics, University of Toronto, ON, Canada

P 22. Reward sensitivity and aggression in bipolar disorder

Robert Haim Belmaker², Yuly Bersudsky², Or Duek¹, Ora Kofman¹, Yamima Osher²

¹Department of Psychology, Faculty of Humanities and Social Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; ²Beer Sheva Mental Health Center, Department of Psychiatry, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel

P 23. Adult Attention Deficit and Hyperactivity Disorder Comorbidity in Obsessive Compulsive Disorder

Bahadır Bakım⁴, Hülya Ertekin¹, Yusuf Ertekin³, Oğuz Karamustafalıoğlu²

¹Konya Education and Research Hospital, Konya, Turkey; ²Şişli Etfal Education and Research Hospital, İstanbul, Turkey; ³Içericiumra State Hospital, Konya, Turkey;

⁴Çanakkale 18 Mart University, Çanakkale, Turkey



P 24. Depression and anxiety disorder comorbidity in patients with obstructive sleep apnea syndrome (OSAS)

Bahadır Bakim¹, Hülya Ertekin², Oguz Karamustafalioglu⁴, Atilla Tekin⁴, Burcu Gokasan Yavuz⁵, Sinan Yayla³

¹Canakkale 18 Mart University Medical Faculty Psychiatry Clinic, Canakkale, Turkey;

²Konya Research and Teaching Hospital, Konya, Turkey; ³Kastamonu State Hospital Psychiatry Clinic, Kastamonu, Turkey; ⁴Sisli Etfal Research and Teaching Hospital, Istanbul, Turkey; ⁵Acibadem University, Istanbul, Turkey

P 25. Biological variables in patients suffering from affective disorders- Metabolic data

Raquel Borrego, Carles Conesa, Antoni Corominas, Anna Falces, Maria-Jose Reyes, Teresa Sarmiento

Hospital de Mollet, Mollet del Valles-Barcelona, Spain

P 26. New Clinical Guidelines in Ireland - Are we listening? A study of Citalopram and Escitalopram prescribing in a large general hospital

O' Dwyer Anne-Marie¹, Martha Finnegan¹, Cooney John¹, Murphy Ross², Guerin Shirley³, Suzanne Smyth¹

¹Department of Psychological Medicine, St James' Hospital., Dublin, Ireland; ²Department of Cardiology, St James' Hospital, Dublin, Ireland; ³Department of Pharmacy, St James' Hospital, Dublin, Ireland

P 27. FDA approved Psychotropic Medications List for Psychiatric Illnesses commonly seen in current US Population and Comparison with Europe

Francisco Fletes, Elizabeth Kwak

Tripler Army Medical Center Department of Psychiatry, Honolulu, USA

P 28. The Development and Psychometric Assessment of a Scale to Measure the Severity of Examination Anxiety among undergraduate University students

Dalia Bedewy¹, Adel Gabriel²

¹Tanta University, Tanta, Egypt, ²University of Calgary, Calgary, Canada



P 29. Differences between depressed escitalopram-treated patients visiting primary and secondary healthcare professionals

Nikolaos Bilanakis¹, Antonios Kodounis², Konstantinos Fokas³, Evaggelos Neroutsos⁴, Eugenia Papalexi⁵, Despoina Giailoglou⁵

¹ Department of Psychiatry, General Hospital of Arta, Arta, Greece, ² Department of Neurology, 251 Air force General Hospital of Athens, Athens, Greece, ³ Department of Psychiatry, General Hospital Papageorgiou, Thessaloniki, Greece, ⁴ Department of Psychiatry, Thriassio General Hospital of Elefsina, Athens, Greece

⁵ Lundbeck Hellas S.A., Athens, Greece

P 30. Potential benefits of slow titration of paroxetine treatment in elderly population

Diana De Ronchi, Sara Giliino, Elisa Mori, Alessandro Serretti

¹Institute of Psychiatry, University of Bologna, Bologna, Italy

P 31. The Effects of D-Cycloserine on Fear Extinction and Expression of zeta-1 subunit of NMDA Receptors in Rats Traumatized with Predator Scent

Aykaç Aslı², Cerit Cem³, Mehmet Zafer Gören⁴, Cabadak Hülya², Çalışkan Mecit¹, Gökçe Sardoğan¹

¹Haydarpaşa Numune Training and Research Hospital, Psychiatry Department, Istanbul, Turkey; ²Marmara University Medical School, Biophysics Department, Istanbul, Turkey;

³Kocaeli University Medical School, Psychiatry Department, Kocaeli, Turkey; ⁴Marmara University Medical School, Medical Pharmacology Department, Istanbul, Turkey

P 32. Depression of bipolarity often diagnosed as Major Depressive Disorder

Anila Hashorva

Kazaferi Anila, Tirana, Albania

P 33. Bipolar disorder often hiding behind alcohol abuse

Anila Hashorva

Dritan Ulqinaku, Tirana, Albania

P 34. The Comparison of the Antidepressant Effects of Zinc, Amantadine and Folic Acid with the Effect of Venlafaxine in the Experimentally Depressed Mice

Ahmet Inal, Nuran Kucuk, Zafer Sezer

Erciyes University Medicine Faculty, Kayseri, Turkey



P 35. Positive psychological resources among Japanese university students with deep depression and anxiety: A study of flow experience and strength-awareness

Ikuo Ishimura¹, Asami Komazawa²

¹Tokyo Seitoku University, Tokyo, Japan; ²Graduate School of Tokyo Seitoku University, Tokyo, Japan

P 36. Adult Attachment Style at Discharge Predicts Depression 4 Months Following a 28-day Alternative Milieu Inpatient Program

Ravindran Arun^{1,2,3}, Grummitt Jessica¹, Brett Jones^{1,3}, Chopra Kevin^{1,2}, Levitan Robert D^{1,2,3}

¹Centre for Addiction and Mental Health, Toronto, Canada; ²University of Toronto, Department of Psychiatry, Toronto, Canada; ³University of Toronto, Institute of Medical Science, Toronto, Canada

P 37. Does light have psychophysiological non-image-forming (NIF)-effects outside of retinohypothalamic tract (RHT)?

Heidi Jurvelin^{1,2}, Lilli Kallio³, Vesa Kiviniemi^{6,7}, Juhani Leppäluoto⁴, Juuso Nissilä^{2,3}, Seppo Saarela³, Tuomo Starck^{6,7}, Timo Takala⁸, Mikko Tulppo⁵, Olli Vakkuri⁴

¹University of Oulu, Institute of Clinical Medicine, Department of Psychiatry, Oulu, Finland; ²University of Oulu, Institute of Health Sciences, Oulu, Finland; ³University of Oulu, Faculty of Science, Department of Biology, Oulu, Finland; ⁴University of Oulu, Faculty of Medicine, Department of Physiology, Oulu, Finland; ⁵Department of Exercise and Medical Physiology, Verve, Oulu, Finland; ⁶Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland; ⁷Department of Diagnostic Radiology, University of Oulu, Oulu, Finland; ⁸Oulu Deaconess Institute, Oulu, Finland

P 38. Gender-specific effects of prenatal exposure to dichlorodiphenyltrichloroethane (DDT) on depressive-like behavior and aryl hydrocarbon receptor signaling in mice

Malgorzata Kajta¹, Wladyslaw Lason¹, Ewa Litwa¹, Irena Nalepa², Joanna Rzemieniec¹, Anna Katarzyna Wojtowicz³, Agnieszka Zelek-Molik²

¹Institute of Pharmacology Polish Academy of Sciences, Department of Experimental Neuroendocrinology, Krakow, Poland; ²Institute of Pharmacology Polish Academy of Sciences, Department of Brain Biochemistry, Krakow, Poland; ³Laboratory of Genomics and Biotechnology, University of Agriculture, Krakow, Poland



P 39. The Relationship of Hopelessness, Anxiety and Depression in a Sample of Freshmen in Meram Medical Faculty

Ayşe Hilal Bati², Nazan Karaoglu¹

¹Necmettin Erbakan University, Meram Medical Facu, Konya, Turkey; ²Ege University, Faculty of Medicine, Izmir, Turkey

P 40. Medical Students' Loneliness, Anxiety and Depression at the Beginning

Ayşe, Hilal Bati², Nazan Karaoglu¹

¹Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey; ²Ege University, Faculty of Medicine, Izmir, Turkey

P 41. Are negative emotions bad? Evaluating emotions and mental health of Japanese children

Masami Kashimura

University of Tsukuba, Tsukuba-shi, Japan

P 42. Predicting factors for utilization of community mental health center following suicide attempt

Sara Hong¹, Yoonha Jang², Hyun Kim³, Min-Hyuk KIM¹, Seongho Min^{1,2}

¹Departement of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, Korea,South; ²Wonju Mental Health Center, Wonju, Korea,South; ³Department of Emergency Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea,South

P 43. Psycho-educational intervention on self-compassion attitude and its effects on depressive symptoms

Kenichi Asano⁴, Kenji Hatori³, Ikuo Ishimura², Kiyoko Koganei¹, Toshiaki Nomura⁵, Nozomi Sukigara⁵, Masahiro Yamaguchi²

¹Ai Clinic Kanda, Tokyo, Japan; ²Tokyo Seitoku University, Tokyo, Japan; ³Saitama Gakuen University, Tokyo, Japan; ⁴Chiba University, Tokyo, Japan; ⁵Nippon Medical School, Tokyo, Japan

P 44. Psychodynamic therapy of reduced mentalisation in depression

Stefan Fleck², André Kümmel¹, Michael Langenbach¹, Rüdiger Mielke², Julia Schütte¹

¹St. Marien-Hospital, Bonn, Germany; ²Cologne University, Cologne, Germany



P 45. Impact of mood and anxiety symptoms on quality of life in patient with CRPS

Do-Hyung Kang^{1,4}, Yong Chul Kim³, Do-Hyeong Lee¹, Eun Jung Noh², Soo Young Park³

¹Department of Neuropsychiatry, Seoul National University Hospital, Seoul; ²Interdisciplinary program of Neuroscience, Seoul National University, Seoul; ³Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul; ⁴Department of Psychiatry, Seoul National University College of Medicine, Seoul, South Korea

P. 46. Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion in an elderly patient

Kim Huat Jason Lee, Pei Lin Lynnette Tan

Tan Tock Seng Hospital, Singapore, Singapore

P 47. Predictors of quit smoking among adolescent students in a public smoking cessation clinic in South Korea

Joon-Ho Ahn, Soo-Young Bhang, Sam-wook Choi, Mikyeong Lee

Department of Psychiatry, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea

P 48. Augmentation of Drug Treatment with Bright Light Therapy in Patients with Difficult-to-Treat Depression: Acute and Long Term Observation

Pietro Bria, Giovanni Camardese, Luigi Janiri, Beniamino Leone, Riccardo Serrani, Mariangela Treglia

Institute of Psychiatry and Clinical Psychology, Catholic University of the Sacred Heart, Rome, Italy

P 49. Behavioral effects of prenatal exposure to 4-para nonylphenol: studies on female and male mice subjected to Novel Object Recognition Test

Malgorzata Kajta, Wladyslaw Lason, Ewa Litwa, Joanna Rzemieniec

Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, Krakow, Poland

P 50. Anxiety in Unipolar and Bipolar Depression (Preliminary Data)

Luchezar Hranov^{1,2}, Petra Marinova^{1,2}

¹University Hospital of Neurology and Psychiatry "Sveti Naum", Sofia, Bulgaria,

²Department of Psychiatry, Medical University, Sofia, Bulgaria



P 51. Mental health of soldiers, made suicide attempts

Mehdiyev Elshad, Azerbaijan

P 52. The epidemiology of neurotic disorders of military personnel.

Mehdiyev Elshad, Azerbaijan

P 53. Impact of mood disorders on family functioning: couples' perspective

Pedro Dias, Bárbara Mendanha, António Roma-Torres, Vânia Sousa-Lima
Catholic University of Portugal, Porto, Portugal

P 54. Attentional set-shifting in children: Effects of individual differences in anxiety and attentional control

Visu-Petra Laura^{1,2}, Mocan Oana^{1,2}, Stanciu Oana³
¹*Developmental Psychology Lab, Cluj-Napoca, Romania;* ²*Babes Bolyai University, Cluj-Napoca, Romania;* ³*University of Edinburgh, Edinburgh, United Kingdom*

P 55. Life stressors and alcohol use in adult men and women: Coping Strategies and alcohol expectancies as mediating factors

Jose Molina Toledo, Lina Ricciardelli
Deakin University, Melbourne, Australia

P 56. The impact of Family Background Experiences to Major Depressive Episodes in Adulthood

Ivandro Monteiro
Instituto Superior da Maia (ISMAI), Maia, Portugal

P 57. Indices of serotonergic neurotransmission is associated with anxiety-related behaviour in rats

Jakob Näslund, Erik Studer, Robert Petterson, Hans Nissbrandt, Elias Eriksson
Department of Pharmacology, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Sweden

P 58. Impact of pain on the outcomes of depression across age and gender

Diego Novick¹, William Montgomery², Jordan Bertsch³, Zbigniew Kadziola⁴, Xiaomei Peng⁵, Roberto Brugnoli⁶, Josep Maria Haro³
¹*Eli Lilly and Company, Windlesham, Surrey, UK;* ²*Eli Lilly Australia Pty Ltd, West Ryde, Australia;* ³*Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain;* ⁴*Eli Lilly GmbH, Vienna, Austria;* ⁵*Eli Lilly and Company, Indianapolis, IN, US;* ⁶*School of Medicine, Department of Neuroscience, University of Rome «Sapienza», Italy.*



P 59. Cognitive Processes when using distraction as an emotion regulation strategy

Toshiki Ogawa²; Chisa Okubo¹

¹University of Tsukuba, Tsukuba, Japan; ²The Open University of Japan, Chiba, Japan

P 60. Ectomorphic somatotype and joint hypermobility as a potential markers for co-morbid anxiety in Schizophrenia

Antonio Bulbena^{1,3,5}, Susana Carmona^{3,4}, Romina Cortizo⁵, Liliana Galindo⁵, Guillem Pailhez^{1,3,5}, Marisol Picado^{2,3}, Oscar Vilarroya^{2,3}

¹Anxiety Disorders Unit - Hospital del Mar, Barcelona, Spain; ²Unitat de Recerca en Neurociència Cognitiva - Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, Spain; ³IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain; ⁴Department of Psychology - Harvard University, Cambridge, USA; ⁵Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar, Barcelona, Spain

P 61. Ectomorphic somatotype and joint hypermobility are linked in panic patients

Carolina Baeza-Velasco⁴, Maria del Mar Ballester³, Antonio Bulbena¹, Juan Castaño², Guillem Pailhez¹, Silvia Rosado¹, Cristina Vendrell³

¹Anxiety Disorders Unit - Hospital del Mar, Barcelona, Spain; ²CSM Sant Martí Sud - Parc de Salut Mar, Barcelona, Spain; ³CAP Ramon Turró - Parc de Salut Mar, Barcelona, Spain; ⁴CHRU Montpellier - Laboratoire Epsilon, Montpellier, France

P 62. Heart Rate Variability in Major Depressive Disorder

Yeon Ho Joo, Byungsu Kim, Jung Sun Lee, Soyeon Park

Asan Medical Center, Seoul, South Korea

P 63. Mood And Anxiety Disorders In a Mental Health Unit

Alfonso Mozos Ansorena², Ana Pampín Alfonso¹, Manuela Pérez García¹, Begoña Portela Traba¹, Lucía Varela Reboiras¹, Iria Veiga Ramos¹

¹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

P 64. Searching for biological markers of mood disorders: monoamines, neurotrophic factors, cellular respiration and related parameters

Jiri Raboch

Psychiatric Department, Charles University in Prague, 1st. School of Medicine, Prague, Czech Rep.



P 65. Rational-Choice Theory of Neurosis: Development and Treatment

Yacov Rofe

Chair Interdisciplinary Dept of Social Sciences Bar Ilan University Ramat Gan, Israel

P 66. Are there reasons to panic? Work insufficiency, poverty, widowing, relationship at risk, encounter with death and/or disability as “candidate stressors”

Katarzyna Cyranka¹, Edyta Dembińska¹, Katarzyna Klasa², Łukasz Müldner-Nieckowski¹, Krzysztof Rutkowski¹, Jerzy A. Sobański¹

¹*Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland;*

²*Department of Psychotherapy, University Hospital, Kraków, Poland*

P 67. Anxiety as a state and trait in the course of PTSD in a group of people persecuted for political reasons in Poland

Katarzyna Cyranka, Edyta Dembińska, Łukasz Müldner-Nieckowski,

Krzysztof Rutkowski, Jerzy A. Sobański

Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland

P 68. The comorbidity of PTSD and depression as a late-onset effect of trauma in a group of people persecuted for political reasons in Poland

Katarzyna Cyranka, Edyta Dembińska, Łukasz Müldner-Nieckowski,

Krzysztof Rutkowski, Jerzy A. Sobański

Department of Psychotherapy, Jagiellonian University Medical College, Kraków, Poland

P 69. Prevalence of Depressive Disorders in Chaharmahal va Bakhtiary Province of Islamic Republic of Iran (2011)

Hassan Palahang¹, Fatemeh Safian¹, Afshin Salahaian²

¹*Shahrekord University of Medical Sciences, Shahrekord, Iran;* ²*University of Isfahan, Isfahan, Iran;*

³*University of Isfahan, Isfahan, Iran*

P 70. Psychosocial and Medical Variables of Depression in HIV/AIDS patients in Kano, Nigeria

Shehu Sale

Aminu Kano, Teaching Hospital, Kano, Nigeria, Kano, Nigeria

P 71. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets

Ligia Westrich¹, Alan Pehrson¹, Huailing Zhong¹, Søren Møller Nielsen²,

Kristen Frederiksen², Tine Bryan Stensbøl², Noel Boyle¹, Morten Hentzer²,

Connie Sanchez¹

¹*Lundbeck Research USA, 215 College Road, Paramus, NJ 07652, USA,* ²*Lundbeck Research DK, Valby, Denmark*



P 72. Living with Depression: A Personal and Professional Perspective

Deborah Serani

Adelphi University, Derner Institute, Garden City, New York, USA

P 73. The effectiveness of life skills training on the happiness of spouses of Iranian veterans (war wounded)

Kamal Solati Dehkordi

Shahrekord University of Medical Sciences, Shahrekord, Iran

P 74 . Associations of depressive symptoms with serum concentrations of thiobarbituric acid reactive substances (TBARS): clinical trials

Dominika Dudek^{1,3}, Gabriel Nowak^{1,4}, Marcin Siwek^{1,3}, Magdalena Sowa-Kucma^{1,2}, Krzysztof Styczen^{1,3}, Bernadeta Szewczyk¹, Leszek Witkowski³

¹Department of Neurobiology, Polish Academy of Sciences, Krakow, Poland; ²Institute of Applied Biotechnology and Basic Sciences, University of Rzeszow, Rzeszow, Poland;

³Department of Psychiatry, Jagiellonian University, Collegium Medicum, Krakow, Poland;

⁴Department of Cytobiology, Jagiellonian University Medical College, Krakow, Poland

P 75. Aviophobia: Evaluation of a treatment program reducing anxiety of flying

Kinnen Danielle, Steffgen Georges, Recchia Sophie

University of Luxembourg, Walferdange, Luxembourg

P 76. Long Term Management Of Major Depression: Difficulties And Challenges

Ileana-Pepita Stoica

Mental Health Centre, Timisoara, Romania

P 77. Impulsivity, executive functions, mild neurological signs and character traits in bipolar disorder patients

Maria Stoyanova

University Hospital for Active Treatment in Neurology and Psychiatry «Sveti Naum», Sofia, Bulgaria

P 78. Does Serotonin Depletion Augment or Counteract the Aggression-Provoking Effect of Testosterone in Mice?

Erik Studer, Jakob Näslund, Erik Andersson, Lars Westberg, Elias Eriksson

Department of pharmacology, University of Gothenburg, Sweden



P 79. Correlation between socio-demographic factors and psychosis at Albanian immigrants returned in Albania

Valbona Alikaj, Anila Hashorva, Valmira Skendi, Elga Spaho, Anastas Suli
University Hospital Center «Mother Teresa», Tirana, Albania

P 80. Perception of Children's anxiety from their Overprotective parents at Albanian Child and Adolescent Psychiatry Clinic

Valbona Alikaj¹, Valmira Skendi¹, Elga Spaho¹, Anastas Suli²
¹*University Hospital Center «Mother Teresa», Tirana, Albania;* ²*School of Medicine, University of Tirana, Tirana, Albania*

P 81. Depression and Generalized Anxiety Disorder in Cancer Patients in Singapore

Kevin Roy Beck, Leslie Lim, Shian Ming Tan
Singapore General Hospital, Singapore, Singapore

P 82. Characteristics of self-compassion and self-disgust on attachment styles

Kenichi Asano⁵, Kenji Hatori⁴, Ikuo Ishimura², Kiyoko Koganei³, Yamaguchi Masahiro², Nozomi Sukigara¹, Nomura Toshiaki¹
¹*Nippon Medical School, Tokyo, Japan;* ²*Tokyo Seitoku University, Tokyo, Japan;* ³*Ai Clinic Kanda, Tokyo, Japan;* ⁴*Saitama Gakuen University, Saitama, Japan;* ⁵*Chiba University, Chiba, Japan*

P 83. Preliminary results on the validation of a French translation of the Screen for Cognitive Impairment in Psychiatry

Philippe Baruch¹, Miriam Beauchamp², Serge Beaulieu³, Richard Bergeron⁴, Florence Chanut⁵, Andrée Daigneault³, Djouini Akram⁶, Charlotte Gagner⁷, Sonia Montmayeur⁹, Mathilde Neugnot⁷, Scott Purdon⁸, Suzanne Renaud³, Evens Villeneuve¹, S. Valérie Tourjman⁶,

¹*Institut universitaire en Santé Mentale de Québec, Université Laval, Québec;* ²*Centre de recherche de l'Hôpital Ste-Justine, Université de Montréal;* ³*Douglas Mental Health University Institute, McGill University, Montréal, Québec;* ⁴*Ottawa Hospital Research Institute, University of Ottawa;* ⁵*Centre hospitalier de l'université de Montréal, Université de Montréal;* ⁶*Centre de recherche Fernand Seguin de Louis H. Lafontaine, Université de Montréal;* ⁷*Département de psychologie, Université de Montréal,* ⁸*Alberta Health Services, University of Alberta, Canada;* ⁹*Faculté de Pharmacie d'Angers, France;*



P 84. Childhood trauma, Resilience and Depression

Giovanni Camardese, Luigi Janiri, Beniamino Leone, Bruna Mattioli, Riccardo Serrani, Mariangela Treglia

Institute of Psychiatry and Clinical Psychology, Catholic University, Rome, Italy

P 85. Early Improvement as a Predictor of Outcome (Response & Readiness for Discharge) in Bipolar I Patients with Manic/ Mixed Episodes: Post-hoc Analyses of Asenapine Studies

A. Guiraud-Diawara², A. Szegedi³, E. Vieta¹, J. Zhao³

¹Hospital Clinic i Universitari de Barcelona, Barcelona, Spain; ²Lundbeck SAS, Issy-les-Moulineaux, France; ³Merck, New Jersey, USA

P 86. A Survey of Patient Preferences for a Placebo Orodispersible Tablet

Gordon Crawford¹, Alan Wade¹, David Young²

¹CPS Research, Glasgow, United Kingdom; ²University of Strathclyde, Glasgow, United Kingdom

P 87. Illuminating the emotional experiences of shame and guilt behind symptoms of depression and anxiety

Eleanor Lin-Er Woodford

Murdoch University, Perth, Australia

P 88. Arts therapies practice with adults suffering from depression in the UK

Vicky Karko, Ania Zubala

Queen Margaret University, Edinburgh, United Kingdom



Audio-Visual Facilities

Speakers must go to the preview room in order to validate and download their presentation files, at least forty minutes before the beginning of the sessions.

Please respect this schedule, otherwise, the performance of the received presentations is not guaranteed.

We cannot accept presentations delivered in room directly (without previewing).

Coffee breaks and midday are the busiest time in the preview room. So we recommend you to come to the preview early in the morning or during other presentations. An hostess will guide and assist the speakers for checking and downloading their presentation files.

European Accreditation

15 UEMS credits have been recognized for this Congress and these credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.

Certificate of Attendance

A certificate of attendance is provided by e-mail after the congress.



CONGRESS VENUE



The “12th International Forum on Mood and Anxiety Disorders” is held at the Hotel Rey Juan Carlos I, Avenida Diagonal, 661-671, Barcelona.



GENERAL INFORMATION



Electricity - Voltage in Spain is 220 volts, and plugs are of the two-pin continental type.

Admission - The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the Congress. Only badge holders is admitted to the appropriate sessions, exhibition and social events.

Language - The official language of the Congress is English. No simultaneous translation is provided.

Insurance - The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants and accompanying persons, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel. The insurance should be purchased in your country of origin.

Secretariat - The secretariat desk will open on Wednesday, November 07th at 11.00 and stay open all through the Congress.

Welcome cocktail - All delegates are cordially invited to attend the Welcome Cocktail which will be held on Wednesday, 07th November at 18.15 in the Hotel Rey Juan Carlos I.



ANNOUNCEMENT OF NEXT FORUM

Save
the date!

13th International Forum on Mood and Anxiety Disorders

will be held in **Monaco**,
13-15 November, 2013





Cipralex - the power to tackle depression^{1,2}

References:

1. Cipriani A et al. Lancet 2009;373:746-58
2. Kennedy SH et al. Curr Med Res Opin 2009;25(1):161-175

Presentation Film-coated tablets 5 10 15 20 mg, oral drops, solution 10 20 mg/ml and orodispersible tablets 10 20 mg. **Indication** Treatment of major depressive episodes, Treatment of panic disorder with or without agoraphobia, Treatment of social anxiety disorder (social phobia), Treatment of generalised anxiety disorder, Treatment of obsessive compulsive disorder. **Dosage** Adults: The recommended starting dose is 10 mg once daily. Depending on individual patient response the dose may be increased to a maximum of 20 mg once daily. An initial starting dose of 5 mg once daily is recommended in the treatment of elderly (>65 years), in panic disorder and in patients with reduced hepatic function. Children and adolescents (< 18 years). Cipralex should not be used in children and adolescents under 18 years of age. Discontinuation: Discontinue gradually over a period of at least one to two weeks to reduce the possibility of discontinuation symptoms. **Contraindications** Hypersensitivity to escitalopram or any other components. Patients with known QT interval prolongation or congenital long

QT syndrome. In combination with MAO-inhibitors or with medicinal products known to prolong the QT interval. Should not be used during pregnancy unless clearly needed and after careful consideration of the risk/benefit ratio. Breast-feeding is not recommended. **Precautions** Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide. It is a general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stage of treatment. Close supervision of highrisk patients should accompany drug therapy. Patients (and caregivers) should be alerted about the need to monitor for emergence of suicidal behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored. SSRIs should be used with caution in patients with a history of mania/hypomania. Treatment with SSRIs may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted. The use of SSRIs/SNRIs has been associated with the development of akathisia. Hyponatraemia has been reported rarely with the use of SSRIs. There have been reports of cutaneous bleeding abnormalities. There have been reports of QT interval prolongation and ventricular

arrhythmia, predominantly in patients of female gender, with hypokalemia, or with pre-existing QT interval prolongation or other cardiac diseases. **Interactions** Caution is advised when taken in combination with MAO-inhibitors or medicinal products known to prolong the QT interval, serotonergic medicinal products, products lowering the seizure threshold, lithium, tryptophan, St. John's Wort, oral anticoagulants or antiplatelet agents (NSAIDs), and products predominantly metabolised by the enzymes CYP2C19 and CYP2D6. **Undesirable effects** Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment. Most commonly occurring: nausea, decreased/increase appetite, weight increased, anxiety, restlessness, abnormal dreams, anorgasmia, insomnia, somnolence, dizziness, paraesthesia, tremor, constipation, vomiting, dry mouth, diarrhoea, sweating increased, arthralgia, myalgia, ejaculation disorder, fatigue and pyrexia. **Overdose** Cases of overdose with escitalopram doses between 400 mg and 800 mg have been reported without any severe symptoms. **Legal category** POM. **Date of preparation or last review** February 2012. **Full Prescribing Information is available from** H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark www.cipralex.com

Lundbeck



Cipralex
escitalopram